Tags

Type your tag names separated by a space and hit enter

High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
MMWR Morb Mortal Wkly Rep. 2006 Jan 20; 55(2):44-6.MM

Abstract

An estimated 200,000 persons are hospitalized each year and 36,000 persons die from complications of influenza in the United States. The cornerstone of influenza prevention is annual vaccination. However, antiviral drugs are an important adjunct to vaccination for influenza prevention and control. Two classes of antiviral medications are available currently: adamantanes or M2 ion channel inhibitors (i.e., amantadine and rimantadine) and neuraminidase inhibitors (i.e., oseltamivir and zanamivir). The adamantanes are active against only influenza A viruses and are used for both treatment and chemoprophylaxis of influenza A, whereas the neuraminidase inhibitors are active against both influenza A and B viruses. Zanamivir is not approved for chemoprophylaxis of influenza in the United States. This report describes new findings regarding the resistance to adamantanes of influenza A viruses currently circulating in the United States and provides interim recommendations that these drugs not be used during the remainder of the 2005-06 influenza season. Amantadine also is used to treat symptoms of Parkinson disease and may continue to be used for this indication.

Authors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16424859

Citation

Centers for Disease Control and Prevention (CDC). "High Levels of Adamantane Resistance Among Influenza a (H3N2) Viruses and Interim Guidelines for Use of Antiviral agents--United States, 2005-06 Influenza Season." MMWR. Morbidity and Mortality Weekly Report, vol. 55, no. 2, 2006, pp. 44-6.
Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006;55(2):44-6.
Centers for Disease Control and Prevention (CDC). (2006). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. MMWR. Morbidity and Mortality Weekly Report, 55(2), 44-6.
Centers for Disease Control and Prevention (CDC). High Levels of Adamantane Resistance Among Influenza a (H3N2) Viruses and Interim Guidelines for Use of Antiviral agents--United States, 2005-06 Influenza Season. MMWR Morb Mortal Wkly Rep. 2006 Jan 20;55(2):44-6. PubMed PMID: 16424859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season. A1 - ,, PY - 2006/1/21/pubmed PY - 2006/1/27/medline PY - 2006/1/21/entrez SP - 44 EP - 6 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb. Mortal. Wkly. Rep. VL - 55 IS - 2 N2 - An estimated 200,000 persons are hospitalized each year and 36,000 persons die from complications of influenza in the United States. The cornerstone of influenza prevention is annual vaccination. However, antiviral drugs are an important adjunct to vaccination for influenza prevention and control. Two classes of antiviral medications are available currently: adamantanes or M2 ion channel inhibitors (i.e., amantadine and rimantadine) and neuraminidase inhibitors (i.e., oseltamivir and zanamivir). The adamantanes are active against only influenza A viruses and are used for both treatment and chemoprophylaxis of influenza A, whereas the neuraminidase inhibitors are active against both influenza A and B viruses. Zanamivir is not approved for chemoprophylaxis of influenza in the United States. This report describes new findings regarding the resistance to adamantanes of influenza A viruses currently circulating in the United States and provides interim recommendations that these drugs not be used during the remainder of the 2005-06 influenza season. Amantadine also is used to treat symptoms of Parkinson disease and may continue to be used for this indication. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/16424859/High_levels_of_adamantane_resistance_among_influenza_A__H3N2__viruses_and_interim_guidelines_for_use_of_antiviral_agents__United_States_2005_06_influenza_season_ L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5502a7.htm DB - PRIME DP - Unbound Medicine ER -